Research Projects Funded or Part Funded by SCaRF
Applicant
Dr Chris
Popham
Mr Robert
Warr
Dr David
Etherington
D Henshaw
Project
5 Projects
Statistical analysis Frenchay
Production of monoclonal antibodies to melanoma
PCR method of detecting tumour cells in the blood of patients
with melanoma
An Ecological Study of Cancer Incidence and Radon Levels
in South West England
A case-control study of Malignant Melanoma in south West
England, including measurement of Radon exposure
Dr John
ICRC Research Laboratory Frenchay
Kempshead
Supervision of work by Dr Zhu and Mr Warr
Dr Ningwen
SCaRF Research Fellow - Published papers include:Zhu
Cutaneous Melanoma – Pathology and Surgical Management.
Sub-lethal effects of exposing the human melanoma cell line
SKmel-23 to 532nm laser light.
Cutaneous malignant melanoma in the young
Prognostic significance of allelic losses in primary melanoma
Changes in the levels of intergrin and focal adhesion kinase
(FAK) in human melanoma cells following 532nm laser
treatment
Dr Chris
What is the relationship between personal phenotype
Bower
characteristics and prognostic histological parameters in
patients with malignant melanoma in the south west of
England.
Prof Jean
A study of the prevalence and aetiology of benign
Golding
melanocytic naevi in childhood as a key to the identification
of precursors of malignant melanoma
Prof S MacNeil Investigation of the protective effect of α-MSH on
Dr N Zhu
inflammation induced melanoma invasion
Dr Julia
An epidemiological study of late relapsing melanoma
Newton Bishop
Dr Tim Eisen
Characterisation of melanocortin receptors on melanoma cell
lines in clinical melanoma samples
Dr Colin
Brn-2 expression controls melanoma proliferation and is
Goding
directly regulated by β-catenin
Dr Jacqui
Travel expenses to present paper at British Association of
Shields
Dermatologists meeting – Presentation of the Shields Index
Mr Rowan
Role of a novel anti-antiogenic iso form of VEGF in skin
Pritchard Jones cancer
15 February 2016
Date
1988-1993
SCaRF
Funding
£11,416
£400
£64,788
1995-1996
£8,000
1993-1996
£11,109
1997-1999
28,750
1994-2000
£132,566
1998-2000
£12,000
1999-2001
£38,162
2002
£18,140
2001-2003
£34,158
2002-2003
£7,520
2001-2003
£5,700
1981-1987
2003
2003-2005
£295
£31,056
Dr Dave Bates
Employment of SCaRF Fellow Mr Darryl Dunn at MicroVascular Laboratories University of Bristol
Dr Victoria
Top up funding to allow the completion of project
Giblin
“Development of a Diagnostic tool for cutaneous melanoma”
Dr Dave Bates Refurbishment of laboratory facilities to enable the culture of
human melanoma cell lines”
Dr Dave Bates “Isolation, identification and characterisation of human
melanoma cell lines”
*Funding for this project obtained from a separate charitable
Trust but administered and monitored by SCaRF
Professor Julia Leading on from findings of her previous research this award
Newton Bishop was made to “ Investigate the possibility that Vitamin A
supplements may have an effect on survival from melanoma”.
Professor
“Cell senescence and the biology of melanoma development”
Dorothy
This application was withdrawn before any payment was actually made
Bennett
2005 - 2009
2006
£20,000
per year
£2,000
2006
£13,500
2006
2006
£5,000
per year
for 3
years
£8,991
2007
£62,002
2007
£50,000
2008-2011
£54,337
2009- 2011
£43,081
2009-2010
£8,000
2009-2011
£25,846
2010-2013
£37,000
2011-2012
£30,610
2011-2012
£32,920
2013- 2014
£56.982
Oct 2013
£4,900
after the applicant succeeded in obtaining funding from another source
Dr Jeanette
Woolard
Katharine
Parker BSc
Dr Jeanette
Woolard
Dr M P Carty
“Dynamic measurement of melanoma using Bioluminescence
Imaging” purchase of a bioluminescence imaging camera
The molecular basis of chemosensitivity of malignant
melanoma to tricyclic anti depressants”
“Impact of small molecular inhibitors in metastatic melanoma”
The response of human keratinocytes and melanocytes to
DNA damage by long wavelength irradiation” purchase of a
UVA irradiation chamber.
Dr R Morgan
“The HOX/PBX interaction as a therapeutic target in
melanoma”
Prof J Newton The establishment of a new research consortium
Bishop
BioGenoMEL
Prof D Bates
Impact of splice factor kinase knockdown in metastatic
melanoma
Mr R
Angiogenesis and metastatic melanoma via the lymphatics.
Pritchard-Jones Resolving the paradox
Dr M Cross
Validation of anti-angiogenesis and anti-lymphangiogenesis as
Mr R Pritchard a potential modality for vemurafenib resistant melanoma
Jones
Dr M Emmett
Dr M Cross
Purchase of cell culture Hood to enable increase in production
Mr R Pritchard of melanoma cell lines
Jones
Mr M Emmett
15 February 2016